MVM Partners today announced the closing of a $325 million healthcare fund, MVM V.
MVM has been investing in high growth healthcare businesses since 1997 and this latest fund, MVM V, will continue this broad, global, investment remit with investments in medical technology, pharmaceuticals, biotechnology, diagnostics, life science tools, and digital health in both private deals and quoted companies. Typical projected investment in each company is $20 to $40 million, but with capacity for larger investments.
In aggregate, MVM has raised investment vehicles totaling over $1 billion which are managed from offices in Boston and London. For more information visit www.mvm.com.
This press release, together with any information or documents accompanying it, is issued by MVM Partners LLP, which is authorised and regulated in the UK by the Financial Conduct Authority.
This document does not constitute an offer or invitation to subscribe or purchase limited partnership interests. Any investment in MVM V LP will be made solely on the basis of the private placement memorandum issued in connection therewith and the limited partnership agreement and associated documentation.
MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022
BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]
MVM Invests in Ossio
October 18, 2022
Proceeds will be used to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber® implants and accelerate new product platforms into the major […]
MVM invests in Neurolens
September 12, 2022
Neurolens, a company commercializing innovative solutions to optimize vision, today announced completion of a $67 million financing. The financing was led by […]
MDxHealth acquires Oncotype DX GPS test
August 2, 2022
MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced it has entered into an […]
Nalu announces new CEO
July 14, 2022
Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today […]
MVM invests in Nalu Medical
February 17, 2022
CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]
Clarivate acquires Patient Connect
December 22, 2021
Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]
MVM invests in Vero Biotech
December 15, 2021
VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the […]
MVM invests In Optinose
November 18, 2021
MVM invested $20 million in Optinose. Optinose markets XHANCE, an innovative drug delivery system that delivers steroids high and deep […]